用于 2 型糖尿病非并发症患者的育阴降糖丸（六味地黄丸）的疗效和安全性：系统评价和荟萃分析的方案。

The efficacy and safety of yukmijihwang-hwan (Liuweidihuang-wan) for type 2 diabetes mellitus without complications: A protocol for systematic review and meta-analysis.

机构信息

Department of Internal Korean Medicine, College of Korean Medicine, Dae-Jeon University, Daejeon, Republic of Korea,Department. of Internal Korean Medicine, College of Korean Medicine, Se-Myung University, Chungcheongbukdo, South Korea.

出版信息

Medicine (Baltimore). 2022 Mar 18;101(11). doi: 10.1097/MD.0000000000029087.

DOI:10.1097/MD.0000000000029087

PMID:35356938

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10684150/

Abstract

BACKGROUND

This systematic review and meta-analysis of randomized controlled trials (RCTs) will aim to assess the efficacy and safety of Yukmijihwang-hwan for type 2 diabetes without complications.

METHODS

To identify eligible studies, we will perform a systematic search of the following electronic databases: MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Citation Information by NII, Korean Information Service System, Korean Medical Database, Oriental Medicine Advanced Searching Integrated System, and ScienceON. Search terms will include "Type 2 Diabetes" for participants as well as "Yukmijihwang-tang" or "Liuwei dihuang tang" for interventions. Two independent researchers will perform data extraction and assessment using Cochrane's risk of bias tool, with disagreements being resolved through discussions with a third researcher.

RESULTS

This study will evaluate the antidiabetic effects of Yukmijihwang-hwan from 3 perspectives (blood glucose level, insulin resistance, and β-cell function) as well as its safety by reviewing the reported adverse effects.

CONCLUSION

This systematic review will provide evidence regarding the antidiabetic efficacy and safety of Yukmijihwang-tang in type 2 diabetes mellitus.

摘要

背景

本系统评价和荟萃分析的随机对照试验（ RCT ）将旨在评估育阴降糖丸治疗 2 型糖尿病无并发症的疗效和安全性。

方法

为了确定合格的研究，我们将进行系统检索以下电子数据库： MEDLINE （ PubMed ）， EMBASE ， Cochrane 中央对照试验注册库，中国国家知识基础设施，日本科学技术振兴机构引文数据库，韩国信息服务系统，韩国医学数据库，东方医学高级检索集成系统，以及科学在线。检索词将包括参与者的“ 2 型糖尿病”以及干预措施的“育阴降糖汤”或“六味地黄丸”。两名独立的研究人员将使用 Cochrane 的偏倚风险工具进行数据提取和评估，如果存在分歧，则通过与第三名研究人员进行讨论来解决。